GlassScriptPhysician profile
Vivek Poudel
NPI 1407581283
$10,330.10
in general payments reported to CMS, 2019-2025
26 companies · $4,374 in 2025
The $4,374 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $290 · 2023: $2,618 · 2024: $3,049 · 2025: $4,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,040.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,820.56 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,079.95 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,030.27 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $762.35 | 2022-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $676.07 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $625.08 | 2024-2025 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $604.05 | 2022-2025 | Trintellix |
| Lundbeck LLC | $592.16 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $557.39 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $353.62 | 2022-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $344.19 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Vanda Pharmaceuticals INC. | $308.66 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $254.92 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $239.44 | 2023-2024 | Ingrezza |
| Validus Pharmaceuticals LLC | $233.13 | 2022-2024 | Equetro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $198.05 | 2022-2025 | Adzenys Xr-Odt, Metadate Cd, Cotempla Xr-Odt |
| Noven Therapeutics, LLC | $109.69 | 2023-2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $101.42 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $96.64 | 2023 | |
| Harmony Biosciences LLC | $91.50 | 2022-2023 | Wakix |
| Ironshore Pharmaceuticals INC. | $55.36 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $49.59 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $42.18 | 2024 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $39.13 | 2024-2025 | Relexxii |
| Owp Pharmaceuticals, INC. | $33.51 | 2023-2024 | Subvenite, Lamotrigine |
| Biogen, INC. | $31.19 | 2024-2025 | Zurzuvae, Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Poudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.